AHS Preview Highlights New Treatments, Biomarkers, and Gut-Brain Topics

Key Takeaways

• The meeting will bring more than 350 abstracts and five plenary sessions to Orlando from June 4-7, 2026.
• The highlighted themes are treatment innovation, biomarkers and personalized medicine, and gut-brain axis topics.
• The schedule also includes abstract sessions, pre-meeting courses, Hot Topics symposia, awards sessions, and career development offerings.

The American Headache Society 68th Annual Scientific Meeting is scheduled for June 4-7, 2026, at the Orlando World Center Marriott in Orlando, Florida, with more than 350 abstracts and five plenary sessions. The program emphasizes new treatments, biomarkers and personalized medicine, and gut-brain axis research, including a new class of migraine treatment in clinical trials and the genetics of a potentially new headache disorder. It also points to talks on the effects of GLP-1 medications on migraine in the clinic, outlining the meeting's scope.

The five plenary sessions are organized around the meeting's main scientific themes. Thursday features New Frontiers in Treatments. Friday includes Sensitization and Placebo and The Ear: Sound and Vestibular Sensitivity, while Saturday turns to Nausea and Gut-Brain Axis Disorders. Sunday closes with Biomarkers, Predictors, and Personalized Medicine in Headache. Together, the plenary sequence forms the meeting's conceptual backbone.

Abstract sessions span preclinical science, epidemiology, diagnosis, and treatment. The program also highlights emerging clinical trial results across treatment classes for migraine and other headache disorders, along with novel management approaches and disease-mechanism research. That mix places basic science alongside clinically oriented discussions of diagnosis and treatment. Under Biomarkers, Predictors, and Personalized Medicine in Headache, the program names blood biomarkers predicting treatment response, digital biomarkers of migraine, and an AI-assisted multimodality-guided personalized treatment discussion. Gut-brain topics include the gut microbiome and migraine, as well as the pathophysiology of nausea.

Beyond the abstract sessions, the schedule includes pre-meeting courses, two concurrent Hot Topics symposia on Saturday, three awards sessions, and career development programming. The pre-meeting courses cover vagus nerve anatomy and therapeutics, migraine patient-reported outcome measures, refractory headache management, and telehealth delivery models. Saturday's Hot Topics sessions focus on cutting-edge basic science and clinical side effects of headache treatments, while the career offerings include mentorship roundtables and National Institutes of Health guidance. Attendees may participate in person or On Demand, and the organization says up to 43.50 AMA PRA Category 1 Credits are available through live and recorded sessions. Together, these elements round out a broad professional and scientific program.

The announcement offers an early look at where headache medicine research is heading. Any references to future patient care remain part of the program description, not evidence of proven benefit. The Orlando meeting is set to preview those directions across treatment, biomarker, and gut-brain research.